Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:TROV

Cardiff Oncology (TROV) Stock Price, News & Analysis

Cardiff Oncology logo

About Cardiff Oncology Stock (NASDAQ:TROV)

Advanced Chart

Key Stats

Today's Range
$4.07
$4.24
50-Day Range
$1.19
$24.71
52-Week Range
$0.70
$3.46
Volume
838,684 shs
Average Volume
648,892 shs
Market Capitalization
$45.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive TROV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cardiff Oncology and its competitors with MarketBeat's FREE daily newsletter.

TROV Stock News Headlines

A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Cardiff Oncology announces second patent for onvansertib combination
See More Headlines

TROV Stock Analysis - Frequently Asked Questions

Cardiff Oncology, Inc. (NASDAQ:TROV) released its quarterly earnings results on Thursday, February, 27th. The medical research company reported ($0.51) earnings per share for the quarter, topping analysts' consensus estimates of ($0.65) by $0.14. The medical research company earned $0.09 million during the quarter. Cardiff Oncology had a negative trailing twelve-month return on equity of 202.00% and a negative net margin of 3,688.31%.

Cardiff Oncology shares reverse split on Wednesday, February 20th 2019.The 1-6 reverse split was announced on Tuesday, February 19th 2019. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 19th 2019. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cardiff Oncology investors own include XOMA Royalty (XOMA), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Bristol Myers Squibb (BMY), OPKO Health (OPK), Alnylam Pharmaceuticals (ALNY) and VBI Vaccines (VBIV).

Company Calendar

Last Earnings
2/27/2020
Today
7/16/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:TROV
CIK
1213037
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($2.80)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$16.41 million
Net Margins
-3,688.31%
Pretax Margin
N/A
Return on Equity
-202.00%
Return on Assets
-122.92%

Debt

Debt-to-Equity Ratio
0.12
Current Ratio
2.37
Quick Ratio
2.37

Sales & Book Value

Annual Sales
$250 thousand
Price / Sales
181.46
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.94 per share
Price / Book
4.38

Miscellaneous

Outstanding Shares
11,011,000
Free Float
N/A
Market Cap
$45.37 million
Optionable
Not Optionable
Beta
1.04
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:TROV) was last updated on 7/16/2025 by MarketBeat.com Staff
From Our Partners